Novo Nordisk’s Acquisition of Three Fill-Finish Sites from Novo Holdings A/S in Conjunction with the Catalent, Inc. Deal
Novo Nordisk has announced its agreement to acquire three fill-finish sites from Novo Holdings A/S as part of the transaction where Novo Holdings will acquire Catalent, Inc., a global contract…
Lilly’s Robust Financial Performance in Q4 2023 and Outlook for 2024 Revealed
Eli Lilly and Company (NYSE: LLY) disclosed its financial outcomes for the final quarter of 2023, marking a year of notable accomplishments characterized by substantial revenue growth. David A. Ricks,…
Japan ATTR-CM Trial Shows Promise for Acoramidis, Mirroring Global Results
Encouraging Outcomes in Japan Phase III Trial of Acoramidis for Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Consistent with Global ATTRibute-CM Phase III Trial Positive high-level results from the Japan Phase III trial…
Extended Study Highlights Persistent Retinal Drying and Vision Enhancement with Roche’s Vabysmo in Retinal Vein Occlusion
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) in macular edema due to branch and central…
Biogen Plans Resource Realignment for Alzheimer’s Disease Franchise
Biogen to Reallocate Resources for Alzheimer’s Disease Franchise Growth Strategy” Biogen Inc. (Nasdaq: BIIB) has unveiled plans to strategically reallocate resources in the Alzheimer’s disease (AD) therapeutic area to drive…
FDA Fast Tracks BioNTech/DualityBio’s Cancer Drug Candidate
FDA Grants Fast Track Designation to BioNTech and DualityBio for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305 BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co., Ltd. (“DualityBio”) today announced that the U.S. Food…
European Medicines Agency Validates Marketing Authorization Application for Tisotumab Vedotin in Treating Recurrent or Metastatic Cervical Cancer
Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE PFE) have announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for tisotumab vedotin, an antibody-drug conjugate…
Labcorp Introduces Innovative Test for Assessing Risk and Predicting Severity of Preeclampsia in Expectant Mothers
Labcorp (NYSE: LH), a renowned provider of cutting-edge and all-encompassing laboratory services globally, has introduced and made accessible a recently FDA-cleared blood test. This test is designed for evaluating the…
Verification of Gamma Wave Synchronization in the Human Brain via Auditory Stimulation: Academic Session at Neuroscience 2023 in the United States
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; referred to as “Shionogi”) has revealed that Pixie Dust Technologies, Inc. (Head Office: Tokyo, Japan; Representative…
Bio-Techne Unveils Fiscal 2024 Second Quarter Financial Performance
Bio-Techne Corporation (NASDAQ: TECH) has released its financial results for the second quarter ending December 31, 2023. Key Highlights for the Second Quarter of Fiscal Year 2024: Bio-Techne’s financial statements…
Advanced Cell Diagnostics by Bio-Techne Establishes a New Benchmark in Spatial Biology with Protease-Free RNAscope Multiomics
Bio-Techne Corporation (NASDAQ: TECH) has unveiled a groundbreaking achievement, as its spatial biology brand, Advanced Cell Diagnostics (ACD), sets a new industry standard. The innovation comes in the form of…
Teva Plans API Business Divestment as a Key Element of Growth-Oriented Strategy
Teva Announces Plan to Sell its Active-Pharmaceutical Ingredient (API) Business, ‘TAPI,’ as a Strategic Move Towards Growth Teva disclosed today its decision to divest its active-pharmaceutical ingredient (API) business, known…